Sutro Biopharma Cash Flow Quality Index
Sutro Biopharma cash flow quality index. Sutro Biopharma (STRO) has a Cash Flow Quality Index of 0.45x as of December 2023. Operating cash flow of $14.07 Million is below net income of $31.07 Million, suggesting accrual-heavy earnings not yet converted to cash. See STRO FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Sutro Biopharma (2016–2016)
Cash flow quality index of Sutro Biopharma from 2016 to 2016. Historical Cash Flow Quality Index for Sutro Biopharma across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Sutro Biopharma cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Sutro Biopharma Cash Flow Quality Index by Year (2016–2016)
Sutro Biopharma cash flow quality index by year from 2016 to 2016. Year-by-year earnings quality comparison for Sutro Biopharma. For the full cash flow conversion analysis, see STRO operating cash flow.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2016 | -7.73x | $-13.15 Million | $1.70 Million | — |